Synonyms: SGC3027; 5'-S-[4-[(N-(3-(2,4,5-trimethyl-3,6-dioxo-cyclohexa-1,4-dienyl)-3-methyl)butyryl)-(N-(4'-chloro-biphenyl-3-ylmethyl)amino]butyl]-5'-thioadenosine; N-(4-((((2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl)thio)butyl)-N-((4'-chloro-[1,1'-biphenyl]-3-yl)methyl)-3-methyl-3-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)butanamide
Molecular Formula: C41H47ClN6O6S
Molecular Weight: 787.37
Linear Structural Formula: C41H47ClN6O6S
Purity: >=98 mg/mL (HPLC)
Storage: -20C
Biochem Physiol Actions: SGC3027 is a selective and cell-active inhibitor of protein arginine N-methyltransferase (PRMT7) It is a pro-drug of the active component, SGC8158, which is produced in the cell by reductases. SGC8158 was shown to inhibit PRMT7 with an IC50 value < 2.5 nM for methylation of H2B (23-37) and greater than 40-fold selectivity over other histone methyltransferases and non-epigenetic targets. SGC3027 inhibited the methylation of HSP70 In cellular assays using C2C12 cells with an IC50 value of 1.3 microM. The closely related SGC3027N is significantly less active in the cellular assay, and is a control compound for cellular studies.